April 22-23 2010, Millenium Bostonian Hotel, Boston

Current trend in escalating R&D expenditure and decreasing productivity levels have put increased pressure on managing the portfolio in order to maximize revenues. Achieving goal of maximized asset base, extending lifecycles, optimal resource allocation, and creating satisfying ROI thru affective prioritization of project portfolio, has become essential in order to maintain a competitive edge and to survive in this challenging period. Thus, efficient project portfolio management guides pharmaceutical companies through periods of slow growth and deliver shareholder confidence in potential future development.

Key Topics included: 

- Effectively Managing Project Portfolio in Changing Economic & Regulatory Environment

- Continued Focus on Resource Allocation & Execution of PPM

- Innovative Strategies & Models for R&D Portfolio Success

- Global Trends in R&D Outsourcing and Partnering

- New Drug Discovery & Risk Management

Chairman was Dr. Markus Thunecke, Senior Partner from Catenion, Germany.

Speaker Panel included several top-level speakers from the industry: